Drug intelligence / Profile preview

furosemide + lysine acetylsalicylate

Development stage: Unknown
Modality: Small Molecules
Administration: Inhalation, Intravenous

Overview

A combination of furosemide, a loop diuretic, and lysine acetylsalicylate, a more soluble form of aspirin. This combination has been studied primarily for its bronchial antireactive activity in asthma patients. The combination demonstrates a synergistic effect that allows for significant reduction in inhaled steroid dosage in patients with severe asthma. The mechanism appears to involve inhibition of local prostaglandin synthesis, which enhances the bronchial antireactive activity of furosemide.

Targets

NKCC2 (Sodium-potassium-chloride cotransporter 2)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on furosemide + lysine acetylsalicylate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on furosemide + lysine acetylsalicylate.

Explore the full profile